Stabilizing Progressive Vitiligo With Systemic Treatment: Identifying Factors Associated With Patients Requiring Prolonged Treatment Duration
Keywords:
active vitiligo, immunosuppressive medications, repigmentationAbstract
Introduction: Patients with active vitiligo are treated with systemic immunosuppressants to halt disease progression. However, clinical features associated with patients whose condition is more difficult to control are unknown.
Objective: This study aimed to identify the clinical features of patients requiring extended periods of systemic immunosuppressants and the real-world clinical course of active vitiligo patients receiving systemic treatments.
Methods: This was a single-center retrospective study. Records of actively progressing vitiligo patients from September 2017 to August 2023 were reviewed.
Results: One hundred and fifty-nine patients with non-segmental actively progressing vitiligo were enrolled. In the six-month follow-up period, 101 (63.52%) patients required oral systemic immunosuppressants for ≤ 16 weeks without reactivation (Group 1), 51 (32.08%) patients required continuous systemic immunosuppressants for more than 16 weeks to achieve disease stabilization (Group 2), and seven (4.4%) patients achieved disease stabilization ≤16 weeks of oral immunosuppressants but recurred within nine months after stabilization (Group 3). Patients in Group 2 were significantly younger (39.69±11.51 vs. 46.47±14.91 years old; P=0.013) and had a lower proportion of facial involvement (56.86% vs. 76.24%; P=0.016) compared to Group 1. Similarly, both age (odds ratio (OR): 0.968; P=0.016) and facial involvement (OR: 0.432; P=0.023) were identified as significant factors associated with decreased risk for Group 2. At one-year follow-up, 10.89% of Group 1 patients experienced disease reactivation.
Conclusions: Older patients and patients with facial involvement were more likely to achieve disease stabilization. Careful photo documentation is essential to optimal vitiligo management as disease reactivation is common after systemic treatment, even if initial disease stabilization is achieved.
References
Ezzedine K, Harris JE. Vitiligo. In: Kang S, Amagai M, Bruckner AL, et al., eds. Fitzpatrick’s Dermatology, 9e. McGraw-Hill Education; 2019. Accessed January 15, 2024. accessmedicine.mhmedical.com/content.aspx?aid=1161324334
Yang TT, Lee CH, Lan CCE. Impact of Vitiligo on Life Quality of Patients: Assessment of Currently Available Tools. Int J Environ Res Public Health. 2022;19(22):14943. DOI:10.3390/ijerph192214943
Böhm M, Schunter JA, Fritz K, et al. S1 Guideline: Diagnosis and therapy of vitiligo. JDDG J Dtsch Dermatol Ges. 2022;20(3):365-378. DOI:10.1111/ddg.14713
Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18-29. DOI:10.1111/bjd.20596
Singh H, Kumaran MS, Bains A, Parsad D. A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo. Dermatology. 2015;231(3):286-290. DOI:10.1159/000433424
Kanwar AJ, Dhar S, Dawn G. Oral Minipulse Therapy in Vitiligo. Dermatology. 1995;190(3):251-252. DOI:10.1159/000246705
Lan CCE, Cheng YP, Hsiao PF, et al. Taiwanese Dermatological Association consensus recommendations for the diagnosis, assessment, and management of vitiligo. Dermatol Sin. 2025;43(1):14-25. DOI:10.4103/ds.DS-D-24-00250
Garza-Mayers AC, Kroshinsky D. Low-dose Methotrexate for Vitiligo. J Drugs Dermatol JDD. 2017;16(7):705-706.
AlGhamdi K, Khurrum H. Methotrexate for the treatment of generalized vitiligo. Saudi Pharm J. 2013;21(4):423-424. DOI:10.1016/j.jsps.2012.12.003
Kanwar AJ, Mahajan R, Parsad D. Low-Dose Oral Mini-Pulse Dexamethasone Therapy in Progressive Unstable Vitiligo. J Cutan Med Surg. 2013;17(4):259-268. DOI:10.2310/7750.2013.12053
Chiu SH, Liu IL, Chen YW, Lan CCE. Low-dose UVB therapy is comparable with conventional UVB phototherapy for treatment of vitiligo: A pilot study. J Dermatol Sci. 2018;92(2):218-220. DOI:10.1016/j.jdermsci.2018.08.006
Singh A, Kanwar A, Parsad D, Mahajan R. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J Dermatol Venereol Leprol. 2014;80(1):29. DOI:10.4103/0378-6323.125479
Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56(2):274-278. DOI:10.1016/j.jaad.2006.09.004
Seneschal J, Duplaine A, Maillard H, et al. Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study. J Invest Dermatol. 2021;141(7):1728-1734. DOI:10.1016/j.jid.2020.12.028
Xu W, Qiu Z, Li C, et al. Recurrence and risk factors in cured patients with vitiligo: A real‐life single‐center retrospective study. J Cosmet Dermatol. 2023;22(5):1680-1684. DOI:10.1111/jocd.15637
Parsad D, Pandhi R, Dogra S, Kumar B. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol. 2004;50(1):63-67. DOI:10.1016/S0190-9622(03)00786-2
Published
Issue
Section
License
Copyright (c) 2025 Ting-Ting Yang, Cheng-Che Lan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
